Lyophilised cagrilintide is most stable as a sealed, dry, cold, dark powder held over desiccant. Moisture governs the dry solid; interfaces and agitation govern the solution. Its amylin lineage makes aggregation the failure mode to watch, and that failure leaves no visible trace on inspection.
- Cagrilintide is an acylated amylin analogue carrying a fatty diacid chain, an intramolecular disulfide bridge and an amidated C-terminus, and each feature is a distinct handling variable.
- No approved cagrilintide product exists to copy storage figures from, so published month counts for research powder are convention rather than measurement.
- Moisture, not freezer temperature, is the dominant driver of degradation in a dry peptide solid.
- The amylin family is amyloidogenic by inheritance, so interfacial stress from vortexing, foaming and freeze-thaw matters more here than for simple hydrophilic sequences.
- Net peptide content on the certificate, not gross fill weight, is what concentration arithmetic should be based on unless the protocol states otherwise.
- Aggregation in a prepared solution is frequently invisible and requires SEC-HPLC or light scattering to detect.
What the molecule is, and what that means for handling
Cagrilintide, identified in the development literature as AM833, is a long-acting analogue of human amylin. Human amylin, also called islet amyloid polypeptide or IAPP, is a 37-residue peptide with an intramolecular disulfide bridge near the N-terminus and an amidated C-terminus. Cagrilintide is an engineered, acylated relative of that parent: a fatty diacid chain is attached to a lysine side chain through a short hydrophilic linker, which gives albumin binding and a long circulating half-life.
I am not going to reproduce a residue-by-residue sequence here. The versions circulating on vendor pages disagree with one another, and a sequence you cannot check against a primary reference does more harm than an honest gap. What matters for storage is not the exact residue list anyway; it is the three structural features that every published description agrees on.
A disulfide bond. An amide at the C-terminus. A lipid chain hanging off the backbone. Each one is a handling variable. The disulfide can scramble or reduce, the amide can hydrolyse, and the lipid makes the molecule interface-active in a way that plain hydrophilic peptides are not. Anyone who has worked with an acylated peptide at low concentration in glass will recognise the third one as the reason material sometimes goes missing without degrading.
Why the usual storage numbers do not exist for this compound
For an approved medicine you can read a storage window off the label, because someone ran a stability programme on that exact formulation, in that exact container, and the number is the outcome of a study. Cagrilintide has no such document to copy from. It has been investigated as a single agent and, more prominently, in fixed combination with semaglutide in late-phase trials, but a research vial of lyophilised powder is not that formulation and never was.
So there is nothing to translate. When a supplier page states that lyophilised cagrilintide is stable for twenty-four months at minus twenty degrees, that figure is a convention borrowed from general peptide practice, not a measurement on that lot. It may well be approximately right. It is still not evidence, and treating it as evidence is how a laboratory ends up unable to explain an assay drift six months into a project.
The defensible position is narrower and duller. Dry, sealed, cold and dark is a slow regime for peptides generally, and cagrilintide has no structural feature that exempts it from that generalisation. Beyond that, the only date entitled to authority is one on a certificate backed by a study on the lot in front of you. Where the certificate carries a retest date with no method behind it, note the absence in your record and move on.
Degradation routes and what controls each
Peptide instability is not mysterious. The chemistry has been catalogued for decades, and the review literature on lyophilised protein and peptide products maps the stresses onto the mechanisms reasonably well. Butreddy and colleagues surveyed that territory in 2020 and their framing still holds: the solid state is slow, water is the switch, and everything else is a rate modifier.
| Route | Driver | Structural feature at risk | Practical control |
|---|---|---|---|
| Backbone hydrolysis | Water activity, temperature, pH in solution | Any amide bond, including the C-terminal amide | Keep the solid dry and sealed over desiccant |
| Deamidation | Water, temperature, pH above roughly 6 | Asparagine and glutamine side chains | Dry storage; cold; controlled pH once dissolved |
| Oxidation | Headspace oxygen, light, trace metals | Methionine, tryptophan, tyrosine, histidine | Dark storage, minimal headspace, no metal contact |
| Disulfide scrambling or reduction | Alkaline pH, free thiols, reducing contaminants | The intramolecular disulfide bridge | Avoid alkaline diluents; keep thiol reagents away from stocks |
| Aggregation and fibrillation | Air-water interface, agitation, concentration, temperature | The amylin backbone plus the lipid chain | Swirl, never vortex; do not foam a solution |
| Surface adsorption | Contact with glass and some plastics | The acylated, amphiphilic whole molecule | Container material fixed and recorded by protocol |
Notice that freezer temperature appears nowhere as a mechanism. Cold slows all six routes, which is why cold storage is standard, but temperature is a multiplier on a rate. Moisture is the thing being multiplied. A sealed vial genuinely dry at room temperature routinely outlasts a vial at minus twenty that gets opened cold twice a week.
The amylin inheritance: aggregation is the family failure mode
Human IAPP is one of the most studied amyloidogenic peptides in biology. Its aggregation into fibrils is implicated in islet pathology in type 2 diabetes, and the region around residues 20 to 29 carries most of the responsibility. Every therapeutic analogue in this family has been engineered against that behaviour. Pramlintide, the earlier analogue, substitutes prolines into the amyloidogenic stretch precisely because the native sequence will not stay in solution long enough to be useful.
Cagrilintide is likewise engineered for solution stability, and it is more tractable than the parent by a wide margin. That is a relative statement, not an exemption. Fibrillation is nucleation-dependent: it has a lag phase, it is accelerated by seeds, and a single aggregate can template the rest of the vial. Interfaces are where nucleation happens most readily, and an acylated peptide concentrates at interfaces by design.
Practical consequences, in order of how often they bite:
- Vortexing a prepared solution whips air into it and creates the interface that seeds aggregation. Gentle swirling until dissolution, then stop.
- A partly filled vial has more air-water surface per unit volume than a full one. Aliquot small, fill reasonably full.
- Freeze-thaw concentrates the peptide at the advancing ice front and cycles it through interfacial stress. The damage accumulates and does not reverse.
- Aggregates are frequently invisible. A solution that looks clear can carry soluble oligomers that size-exclusion chromatography would reveal and your eye will not.
If a project depends on knowing the aggregation state, the analytical answer is SEC-HPLC or dynamic light scattering on the prepared solution, not inspection under a bench lamp.
Storage conditions by physical state
| State | Temperature | Light | Relative horizon | Reasoning |
|---|---|---|---|---|
| Sealed powder, unopened | Minus 20 °C or colder, desiccated | Dark | Longest | Water excluded and every route slowed |
| Sealed powder, in-use stock | 2 to 8 °C | Dark | Shorter | Acceptable where the vial is consumed inside a defined window |
| Powder in transit | Ambient, insulated | Dark | Days | A dry solid tolerates short excursions that a solution would not |
| Prepared aqueous solution | 2 to 8 °C | Dark | Days, not months | Hydrolysis, deamidation and aggregation are all running |
| Solution, single-use aliquots | Minus 20 °C or colder | Dark | Longer, at a cost per thaw | Freeze-thaw stress is traded for storage time |
The horizons are relative on purpose. Putting a month count against a research powder implies a stability study that, for this compound, almost certainly has not been run on your lot in your container. Where a laboratory needs a working window it should set one by protocol, document the reasoning, and requalify by assay rather than by calendar faith. That is more work than reading a number off a webpage, and it is the only version that survives an audit.
Condensation, the loss nobody logs
A vial coming out of a minus twenty freezer into a room at 22 °C and sixty percent humidity is far below the dew point. Water condenses on every cold surface, including the interior the instant the seal is broken, and a lyophilised cake is hygroscopic enough to absorb it before you have finished reading the label. Nothing about the cake announces this. It looks the same.
Then the vial goes back into the freezer with water inside it, and hydrolysis and deamidation now have a substrate they did not have yesterday. Repeat weekly for two months and the material genuinely is not what the certificate described, with no single event in the log to point at.
The control is boring and it works. Let the sealed vial equilibrate to room temperature before breaking the seal, every time, including when you are in a hurry. Twenty to thirty minutes on the bench suits a small vial. Work quickly once it is open, reseal against fresh desiccant, and record the excursion if your protocol tracks them.
Drier is not infinitely better, incidentally. Work on lyophilisate formulations has found cases where raising residual moisture modestly improved stability, because water can substitute for hydrogen bonds the excipient matrix fails to supply. That is a formulation result rather than a storage instruction, and the reason to mention it is to make clear that the rule of thumb has edges.
Once diluent goes in
Adding diluent starts the fast clock. Everything in the degradation table that needed water now has it, the amphiphilic character of the molecule has an interface to work on, and any organism introduced during preparation has a medium. Two practices carry most of the benefit: aliquot into single-use containers at the moment of preparation, and date every container then rather than later.
Choice of diluent belongs in the record too. Bacteriostatic water and plain sterile water are not the same solvent and do not behave identically over time; the comparison of diluents used for peptide work sets out what differs. Alkaline buffers deserve particular caution here, because pH above neutral accelerates both deamidation and thiol-disulfide exchange, and this molecule has a disulfide worth protecting.
Worked arithmetic, since the question comes up in every method review. A 5 mg vial brought into 2 mL of diluent gives:
5 mg ÷ 2 mL = 2.5 mg/mL
If a protocol consumes 0.25 mL per run, one container supports:
2 mL ÷ 0.25 mL = 8 draws
Held as a single container, the eighth draw comes from material that has been warmed and re-chilled seven times, each cycle adding interfacial stress to a peptide from an aggregation-prone family. Split into eight aliquots at preparation, every sample sees one thaw. The cost is a rack of tubes and five minutes. The vial concentration calculator handles other vial and volume combinations; it is a measurement tool and nothing more.
One further note on net content. If the certificate reports peptide content as, say, 84 percent with the balance as acetate counterion and water, then the mass in the vial is not all peptide, and a concentration calculated from gross fill weight overstates the true figure. Whether your protocol works from gross or net mass should be a written decision, not an assumption inherited from whoever set the method up.
What the certificate and the record should show
Storage discipline that is not written down cannot be reproduced. For the incoming material, the certificate of analysis is the object under review, and for a compound like this the fields that matter are specific.
| Field | Typical method | What it tells you |
|---|---|---|
| Identity | LC-MS or MALDI | Whether the observed mass matches the acylated species rather than an unacylated precursor |
| Purity | RP-HPLC, 214 nm, gradient stated | Chromatographic purity, provided the trace itself is attached |
| Disulfide status | Free thiol assay, or reduced versus non-reduced comparison | Whether the bridge formed and stayed formed |
| Water content | Karl Fischer or loss on drying | The starting point of the storage clock |
| Counterion and net peptide content | Ion chromatography, amino acid analysis | How much of the fill weight is actually peptide |
For the prepared solution, the record carries the source lot, the diluent and its lot, the volume added, the resulting concentration, the date and time, and the initials of whoever prepared it. Aliquots inherit that through a shared identifier written on the tube in something that survives frost. When a result comes out wrong, the first question is always whether the material was what the method assumed, and a chain that runs sample to aliquot to solution to lot to certificate answers it in about a minute. The alternative is repeating the experiment.
Regulatory position
Cagrilintide is an amylin receptor agonist investigated by its originator both alone and in fixed combination with semaglutide in late-stage clinical trials. As reviewed for this article, no approved medicine containing cagrilintide had been confirmed by this reviewer in the United States. Approval status for a compound at this stage of development moves, and the FDA drug listings are the only authority worth quoting on any given day.
An unapproved investigational active ingredient is not eligible for pharmacy compounding under section 503A unless it is a component of an approved drug, the subject of an applicable USP monograph, or listed on the FDA bulk drug substances list. Research-grade cagrilintide meets none of those conditions and has never been a lawful route to human use.
Status verified 26 August 2026. Confirm against FDA listings before relying on it.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Laboratories comparing handling practice across acylated peptides may find the tirzepatide storage discussion useful, since the interface behaviour of a fatty-diacid conjugate is the same problem in a different sequence. Lot documentation for material supplied here is described under the quality standard.
Common questions
Does lyophilised cagrilintide have to be stored frozen?
Is cagrilintide more aggregation-prone than other research peptides?
How long is a prepared solution good for?
Why does diluent pH matter for this compound in particular?
What should a certificate of analysis show for an acylated peptide?
Can a thawed aliquot be refrozen?
Sources
- Butreddy et al., International Journal of Biological Macromolecules, 2020. Review of stresses, stabilisation mechanisms and analytical techniques for lyophilised protein products; supports the degradation-route table and the primacy of solid-state, low-moisture storage.
- Akter and colleagues. Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology. Journal of Diabetes Research 2016:2798269 . Basis for the aggregation cautions in this article — the review sets out the fibrillation behaviour of human islet amyloid polypeptide and the conditions that accelerate it.
- ICH Q1A(R2) and Q5C stability testing guidelines. Define what a stability-derived shelf life requires: study design, container-closure, storage condition and assay. Supports the position that an unsupported month count on a research vial is not evidence.
- FDA guidance and listings on compounding under sections 503A and 503B. Establishes the eligibility conditions for bulk drug substances in compounding, and therefore that an unapproved investigational peptide is not a lawful compounding ingredient.